Can treatment choice affect cost of therapy in patients predicted to be high-responders? Results of an economic analysis of the menopur in GnRH antagonist single embryo transfer - high responder (MEGASET-HR) trial

Abstract

miR-200c, let-7d-3p and miR-150-5p) were selected for a subsequent validation set. The results showed that the serum levels of miR-181d-5p was significantly increased in the HR group when compared with LR group (p¼ 0.0002) and NR group (p¼ 0.0091). No differences were observed between NR and PR groups (p¼0.2772). Serum levels of miR-181d-5p was also positively correlated with the number of aspirated follicles (p<0.0001), number of retrieved oocytes (p<0,0001), and number of mature oocytes (p¼0.0002).CONCLUSIONS: The quantification of miR-181d-5p prior to the COS may discriminate patients who will respond in an exacerbated manner to those who will respond insufficiently to the COS. The use of this tool associated with other previously described parameters may allow the individualization of the treatment, increasing treatment success while decreasing patients' risks and physical, emotional and economic burden.